Received Oct 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| FLU3 | INFLUENZA (SEASONAL) (FLULAVAL) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 5EF45 | — |
Flulaval was used as the diluent to reconstitute Merck and MMR II and Varivax vaccine; Flulaval was used as the diluent to reconstitute Merck and MMR II and Varivax vaccine; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate preparation of medication in a 12-month-old patient who received Flu Seasonal TIV Quebec (FluLaval 2025-2026 season) (batch number 5EF45, expiry date 09-JUN-2026) for prophylaxis. On 08-SEP-2025, the patient received FluLaval 2025-2026 season. On 08-SEP-2025, an unknown time after receiving FluLaval 2025-2026 season, the patient experienced inappropriate preparation of medication (Verbatim: Flulaval was used as the diluent to reconstitute Merck and MMR II and Varivax vaccine) and inappropriate dose of vaccine administered (Verbatim: Flulaval was used as the diluent to reconstitute Merck and MMR II and Varivax vaccine). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 09-SEP-2025 The registered nurse reported that Flulaval was mistakenly used as the diluent to reconstitute Merck's MMR II and Varivax vaccines. Due to this reconstitution error, the patient inadvertently received two doses of Flulaval.